GOLDMAN SACHS GROUP INC - Y-MABS THERAPEUTICS INC ownership

Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 97 filers reported holding Y-MABS THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.24 and the average weighting 0.1%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of Y-MABS THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$2,121,941
-22.4%
389,347
-3.3%
0.00%
-100.0%
Q2 2023$2,734,000
+186.0%
402,651
+111.0%
0.00%
Q1 2023$955,863
-38.2%
190,791
-39.8%
0.00%
Q4 2022$1,546,237
-41.4%
316,852
+73.1%
0.00%
-100.0%
Q3 2022$2,640,000
+15.0%
183,077
+20.7%
0.00%0.0%
Q2 2022$2,296,000
+53.3%
151,726
+20.3%
0.00%
Q1 2022$1,498,000
-57.5%
126,111
-42.0%
0.00%
-100.0%
Q4 2021$3,523,000
-84.8%
217,361
-73.3%
0.00%
-80.0%
Q3 2021$23,213,000
-16.3%
813,355
-0.9%
0.01%
-16.7%
Q2 2021$27,733,000
+12.1%
820,482
+0.3%
0.01%0.0%
Q1 2021$24,732,000
-42.0%
817,849
-5.1%
0.01%
-45.5%
Q4 2020$42,650,000
+53.0%
861,438
+18.6%
0.01%
+37.5%
Q3 2020$27,876,000
+11.3%
726,117
+25.2%
0.01%0.0%
Q2 2020$25,050,000
+94.0%
579,878
+17.2%
0.01%
+60.0%
Q1 2020$12,910,000
-28.4%
494,641
-14.3%
0.01%0.0%
Q4 2019$18,026,000
+163.5%
576,846
+119.8%
0.01%
+150.0%
Q3 2019$6,840,000
+32.4%
262,456
+16.2%
0.00%
+100.0%
Q2 2019$5,166,000
-12.3%
225,867
+0.5%
0.00%
-50.0%
Q1 2019$5,891,000
+21.8%
224,765
-5.5%
0.00%0.0%
Q4 2018$4,836,000
-41.5%
237,778
-23.6%
0.00%0.0%
Q3 2018$8,266,000311,2100.00%
Other shareholders
Y-MABS THERAPEUTICS INC shareholders Q2 2023
NameSharesValueWeighting ↓
Sofinnova Investments, Inc. 2,104,278$55,890,0004.98%
SCOPIA CAPITAL MANAGEMENT LP 1,587,566$42,166,0000.81%
DC Investments Management, LLC 25,000$664,0000.45%
Monashee Investment Management LLC 67,800$1,801,0000.38%
Avoro Capital Advisors LLC 310,000$8,234,0000.38%
Cormorant Asset Management, LP 200,000$5,312,0000.34%
PURA VIDA INVESTMENTS, LLC 22,350$594,0000.12%
Artal Group S.A. 150,000$3,984,0000.10%
OXFORD ASSET MANAGEMENT LLP 59,122$1,556,0000.03%
Point72 Hong Kong Ltd 3,252$86,0000.03%
View complete list of Y-MABS THERAPEUTICS INC shareholders